INNATE PHARMAINNATE PHARMAINNATE PHARMA

INNATE PHARMA

No trades
See on Supercharts

Price target

6.580.000.00%
The 6 analysts offering 1 year price forecasts for IPH have a max estimate of — and a min estimate of —.

Analyst rating

Based on 6 analysts giving stock ratings to IPH in the past 3 months.

EPS

Reported
Estimate
Reported
Estimate
Surprise

Revenue

Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


IPH EPS for the last quarter is −0.31 EUR despite the estimation of −0.28 EUR. In the next quarter EPS is expected to reach −0.26 EUR. Track more of INNATE PHARMA financials and stay on top of what is up with the company.
In the next quarter INNATE PHARMA revenue is expected to reach ‪17.32 M‬ EUR. Check out INNATE PHARMA revenue and earnings and make informed decisions.
According to analysts, IPH price target is 6.58 EUR with a max estimate of 10.89 EUR and a min estimate of 2.41 EUR. Check if this forecast comes true in a year, meanwhile watch INNATE PHARMA stock price chart and keep track of the current situation with IPH news and stock market news.
We've gathered opinions of 6 analysts rating IPH stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.